Shopping Cart 0
Cart Subtotal
USD 0

CEL-SCI Corp (CVM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI's lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corp (CVM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13

Cel-Sci Expands Co-Development Agreement with Ergomed 14

Equity Offering 15

CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15

CEL-SCI Raises USD5 Million in Private Placement of Shares 16

CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17

CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18

CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19

CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20

CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21

CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22

CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23

CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25

CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26

CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28

CEL-SCI Raises USD5 Million in Registered Direct Offering 29

CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30

CEL-SCI Raises USD1.1 Million in Private placement of Shares 31

Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32

Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34

CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35

Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36

Cel-Sci Raises USD3 Million upon Exercise of Warrants 38

Cel-Sci Completes Public Offering Of Units For USD 10 Million 39

Cel-Sci Completes Public Offering Of Units For USD 3.3 Million 40

Cel-Sci Completes Public Offering Of Units For USD 17.8 Million 42

Cel-Sci Completes Public Offering Of Common Stock For USD 11 Million 44

Cel-Sci Files Registration Statement For Public Offering Of Securities For USD 50 Million 45

Cel-Sci Completes Private Placement Of Common Stock For USD 6 Million 46

CEL-SCI Completes Private Placement Of Common Stock For USD 5.8 Million 47

Debt Offering 48

CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48

CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49

CEL-SCI Corp-Key Competitors 50

CEL-SCI Corp-Key Employees 51

CEL-SCI Corp-Locations And Subsidiaries 52

Head Office 52

Recent Developments 53

Financial Announcements 53

Aug 14, 2018: CEL-SCI reports third quarter fiscal year 2018 financial results 53

May 15, 2018: CEL-SCI Announces Second Quarter Fiscal 2018 Financial Results 54

Feb 12, 2018: CEL-SCI Reports First Quarter Fiscal 2018 Financial Results 55

Dec 29, 2017: CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments 56

Aug 09, 2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results 57

May 10, 2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results 58

Feb 09, 2017: CEL-SCI Reports First Quarter Fiscal 2017 Financial Results 59

Corporate Communications 60

Aug 17, 2018: CEL-SCI Announces that the NYSE American approves plan 60

Dec 18, 2017: CEL-SCI Announces Robert Watson Joins its Board of Directors 61

Feb 27, 2017: CEL-SCI Announces That the NYSE MKT Approves Plan 62

Government and Public Interest 63

Sep 19, 2017: CEL-SCI Announces USD 1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine 63

Product News 64

05/16/2017: CEL-SCI Scientist Presents Data on CEL-4000 at AAI-IMMUNOLOGY 2017 Meeting 64

04/12/2017: CEL-SCI Scientist Presents at the World Vaccine Congress 65

02/21/2017: CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference 66

Clinical Trials 67

Jun 08, 2017: CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal 67

Other Significant Developments 68

Jun 11, 2018: CEL-SCI Issues Letter to Shareholders 68

Apr 04, 2018: CEL-SCI: Letter to Shareholders 69

Jan 03, 2018: CEL-SCI Releases Letter to Shareholders 70

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CEL-SCI Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CEL-SCI Corp, Deals By Therapy Area, 2012 to YTD 2018 9

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13

Cel-Sci Expands Co-Development Agreement with Ergomed 14

CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15

CEL-SCI Raises USD5 Million in Private Placement of Shares 16

CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17

CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18

CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19

CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20

CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21

CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22

CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23

CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25

CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26

CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28

CEL-SCI Raises USD5 Million in Registered Direct Offering 29

CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30

CEL-SCI Raises USD1.1 Million in Private placement of Shares 31

Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32

Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34

CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35

Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36

Cel-Sci Raises USD3 Million upon Exercise of Warrants 38

Cel-Sci Completes Public Offering Of Units For USD 10 Million 39

Cel-Sci Completes Public Offering Of Units For USD 3.3 Million 40

Cel-Sci Completes Public Offering Of Units For USD 17.8 Million 42

Cel-Sci Completes Public Offering Of Common Stock For USD 11 Million 44

Cel-Sci Files Registration Statement For Public Offering Of Securities For USD 50 Million 45

Cel-Sci Completes Private Placement Of Common Stock For USD 6 Million 46

CEL-SCI Completes Private Placement Of Common Stock For USD 5.8 Million 47

CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48

CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49

CEL-SCI Corp, Key Competitors 50

CEL-SCI Corp, Key Employees 51

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

CEL-SCI Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI's lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.

CEL-SCI Corp (CVM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13

Cel-Sci Expands Co-Development Agreement with Ergomed 14

Equity Offering 15

CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15

CEL-SCI Raises USD5 Million in Private Placement of Shares 16

CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17

CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18

CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19

CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20

CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21

CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22

CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23

CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25

CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26

CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28

CEL-SCI Raises USD5 Million in Registered Direct Offering 29

CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30

CEL-SCI Raises USD1.1 Million in Private placement of Shares 31

Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32

Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34

CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35

Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36

Cel-Sci Raises USD3 Million upon Exercise of Warrants 38

Cel-Sci Completes Public Offering Of Units For USD 10 Million 39

Cel-Sci Completes Public Offering Of Units For USD 3.3 Million 40

Cel-Sci Completes Public Offering Of Units For USD 17.8 Million 42

Cel-Sci Completes Public Offering Of Common Stock For USD 11 Million 44

Cel-Sci Files Registration Statement For Public Offering Of Securities For USD 50 Million 45

Cel-Sci Completes Private Placement Of Common Stock For USD 6 Million 46

CEL-SCI Completes Private Placement Of Common Stock For USD 5.8 Million 47

Debt Offering 48

CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48

CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49

CEL-SCI Corp-Key Competitors 50

CEL-SCI Corp-Key Employees 51

CEL-SCI Corp-Locations And Subsidiaries 52

Head Office 52

Recent Developments 53

Financial Announcements 53

Aug 14, 2018: CEL-SCI reports third quarter fiscal year 2018 financial results 53

May 15, 2018: CEL-SCI Announces Second Quarter Fiscal 2018 Financial Results 54

Feb 12, 2018: CEL-SCI Reports First Quarter Fiscal 2018 Financial Results 55

Dec 29, 2017: CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments 56

Aug 09, 2017: CEL-SCI Reports Third Quarter Fiscal Year 2017 Financial Results 57

May 10, 2017: CEL-SCI Reports Second Quarter Fiscal Year 2017 Financial Results 58

Feb 09, 2017: CEL-SCI Reports First Quarter Fiscal 2017 Financial Results 59

Corporate Communications 60

Aug 17, 2018: CEL-SCI Announces that the NYSE American approves plan 60

Dec 18, 2017: CEL-SCI Announces Robert Watson Joins its Board of Directors 61

Feb 27, 2017: CEL-SCI Announces That the NYSE MKT Approves Plan 62

Government and Public Interest 63

Sep 19, 2017: CEL-SCI Announces USD 1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine 63

Product News 64

05/16/2017: CEL-SCI Scientist Presents Data on CEL-4000 at AAI-IMMUNOLOGY 2017 Meeting 64

04/12/2017: CEL-SCI Scientist Presents at the World Vaccine Congress 65

02/21/2017: CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference 66

Clinical Trials 67

Jun 08, 2017: CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal 67

Other Significant Developments 68

Jun 11, 2018: CEL-SCI Issues Letter to Shareholders 68

Apr 04, 2018: CEL-SCI: Letter to Shareholders 69

Jan 03, 2018: CEL-SCI Releases Letter to Shareholders 70

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CEL-SCI Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CEL-SCI Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CEL-SCI Corp, Deals By Therapy Area, 2012 to YTD 2018 9

CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 12

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 13

Cel-Sci Expands Co-Development Agreement with Ergomed 14

CEL-SCI Plans to Raise up to USD100 Million in Public Offering of Shares 15

CEL-SCI Raises USD5 Million in Private Placement of Shares 16

CEL-SCI Raises USD2.1 Million in Private Placement of shares up on Exercise of Warrants 17

CEL-SCI Files Registration Statement to Raise up to USD11 Million in Private Placement of Shares 18

CEL-SCI to Raise up to USD2.5 Million in Public Offering of Shares 19

CEL-SCI Raises USD2.4 Million in Private Placement of Shares and Warrants 20

CEL-SCI to Raise USD3.5 Million in Private Placement of Shares and Warrants 21

CEL-SCI to Raise USD2 Million in Private Placement of Shares upon Exercise of Warrants 22

CEL-SCI Raises USD1.5 Million in Private Placement of Shares and Warrants 23

CEL-SCI Raises USD1 Million in Private Placement of Shares and Warrants 25

CEL-SCI Raises USD4.3 Million in Public Offering of Shares 26

CEL-SCI Raises USD5 Million in Private Placement of Shares and Warrants 28

CEL-SCI Raises USD5 Million in Registered Direct Offering 29

CEL-SCI Raises USD0.6 Million in Priavte Palcement of Shares 30

CEL-SCI Raises USD1.1 Million in Private placement of Shares 31

Cel-Sci Raises USD11.5 Million in Public Offering of Shares and Warrants 32

Cel-Sci Raises USD16 Million in Public Offering of Shares and Warrants 34

CEL-SCI Raises USD16 Million in Public Offering of Shares and Warrants 35

Cel-Sci Raises USD6 Million in Public Offering of Shares and Warrants 36

Cel-Sci Raises USD3 Million upon Exercise of Warrants 38

Cel-Sci Completes Public Offering Of Units For USD 10 Million 39

Cel-Sci Completes Public Offering Of Units For USD 3.3 Million 40

Cel-Sci Completes Public Offering Of Units For USD 17.8 Million 42

Cel-Sci Completes Public Offering Of Common Stock For USD 11 Million 44

Cel-Sci Files Registration Statement For Public Offering Of Securities For USD 50 Million 45

Cel-Sci Completes Private Placement Of Common Stock For USD 6 Million 46

CEL-SCI Completes Private Placement Of Common Stock For USD 5.8 Million 47

CEL-SCI Raises USD1.2 Million in Private Placement of 4% Notes Due 2017 48

CEL-SCI Raises USD1.5 Million in Private Placement of 4% Notes Due 2017 49

CEL-SCI Corp, Key Competitors 50

CEL-SCI Corp, Key Employees 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

CEL-SCI Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.